FDA Weighs Lilly, Amgen Findings On Cancer Drugs

By Sara Stefanini (December 12, 2008, 12:00 AM EST) -- The U.S. Food and Drug Administration has asked an advisory committee to consider whether clinical studies by Amgen Inc. and ImClone Systems Inc. are strong enough to show that their respective cancer drugs, Vectibix and Erbitux, are more likely to help patients with a nonmutated rather than a mutated form of a certain gene....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!